Novartis Signs Up to $7.8 Billion mRNA Deal With China's Abogen, Paying $575 Million Upfront

SentiSense · Published Oct 2, 2026, 9:44 AM ET · Updated Oct 2, 2026, 1:59 PM ET

Novartis signed a licensing deal with China's Abogen Biosciences worth up to $7.8 billion, paying $575 million upfront for an option on ABO2203, an mR...